Genmab | GEN - Current Assets


Genmab reported DKK2.8B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Agios Pharmaceuticals USD 717.67M 117.18M Jun/2026
Almirall EUR 747.1M 33.12M Jun/2026
Amarin USD 602.76M 23.26M Jun/2026
Amgen USD 34.96B 3.49B Jun/2026
argenx SE USD 8.07B 1.17B Jun/2026
AstraZeneca USD 27.97B 1.65B Jun/2026
Bayer EUR 33.64B 1.66B Jun/2026
BioMarin Pharmaceutical USD 3.97B 633.45M Jun/2026
Demant DKK 10.2B 130M Jun/2026
Exelixis USD 1.25B 42.18M Jun/2026
Fresenius Medical Care EUR 7.69B 418.66M Jun/2026
Genmab DKK 2.8B 228M Jun/2026
GlaxoSmithKline GBP 17.56B 202M Jun/2026
GN Store Nord DKK 5.63B 783M Jun/2026
GRIFOLS EUR 5.31B 51M Jun/2026
Hikma Pharmaceutical USD 2.64B 86M Dec/2025
Insmed USD 1.63B 20.75M Jun/2026
Lakefront Biotherapeutics EUR 2.31B 751.38M Jun/2026
Lonza CHF 8B 3.41B Dec/2025
Merck EUR 13.77B 393M Jun/2026
Novartis USD 27.35B 744M Jun/2026
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sanofi EUR 31.52B 1.36B Jun/2026
UCB EUR 6.05B 733M Dec/2025